21. EVALUATION OF QUALITY OF LIFE IN STAGE IV LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY
Main Article Content
Abstract
Objective: This study aimed to evaluate the QoL of stage IV lung cancer patients treated with immunotherapy alone or in combination with chemotherapy and to analyze factors influencing QoL after treatment.
Materials and Methods: This prospective descriptive study enrolled 33 patients with stage IV lung cancer treated either immunotherapy alone or combined with chemotherapy at Internal Medicine Department 2, K Hospital, from October 2022 to October 2023. Assessment of life quality was conducted using two validated instruments: the EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires.
Results: The EORTC QLQ-C30 questionnaire showed significant improvement in all functional areas (physical functioning, role functioning, social functioning, emotional functioning, and cognitive functioning) and in certain symptom aspects (fatigue, pain, and dyspnea) after four cycles of immunotherapy (p < 0.05). Financial difficulties increased significantly when comparing before and after treatment (p < 0.05). According to the EORTC QLQ-LC13 questionnaire, symptoms of cough, dyspnea, pain, and peripheral neuropathy improved after four treatment cycles (p < 0.05). The patient's performance status (PS) at the beginning of treatment was found to be related to patients' quality of life after treatment. There was no significant difference in QoL between the monotherapy and combination therapy regimens, except for symptoms related to chemotherapy toxicity.
Conclusion: Immunotherapy regimens, either as alone or in combination with chemotherapy, provide significant symptom relief and QoL improvement for patients with stage IV lung cancer after four cycles of treatment.
Article Details
Keywords
quality of life, immunotherapy, lung cancer
References
[2] Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. European journal of cancer (Oxford, England : 1990). 1994;30a(5):635-642.
[3] Kaasa S, Bjordal K, Aaronson N, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. European journal of cancer (Oxford, England : 1990). Dec 1995;31a(13-14):2260-2263.
[4] Liu W, Zhang Q, Zhang T, Li L, Xu C. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. World Journal of Surgical Oncology. 2022/10/04 2022;20(1):333.
[5] Pérol M, Dixmier A, Barlesi F, et al. Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study. Annals of Oncology. 2019;30:ii48.
[6] Hensing T, Cella D, Yount S. The impact of ECOG performance status on quality of life symptoms in patients with advanced lung cancer. Journal of Clinical Oncology. 2005/06/01 2005;23(16_suppl):8099-8099.
[7] Roughley A, Damonte E, Taylor-Stokes G, Rider A, Munk VC. Impact of Brain Metastases on Quality of Life and Estimated Life Expectancy in Patients with Advanced Non-Small Cell Lung Cancer. Value in Health. 2014;17(7):A650.
[8] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. Nov 10 2016;375(19):1823-1833.